The effect of omalizumab treatment on severe allergic asthma and allergic comorbidities: real-life experience from the Czech Anti-IgE Registry

INTRODUCTION: Omalizumab is indicated for the treatment of severe allergic asthma (SAA) and chronic spontaneous urticaria, although a number of studies have confirmed the effectiveness of this therapy also for other IgE-mediated diseases. AIM: To assess the impact of anti-IgE therapy on SAA and como...

Descripción completa

Detalles Bibliográficos
Autores principales: Hutyrová, Beáta, Bystroň, Jaromír
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2018
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6232552/
https://www.ncbi.nlm.nih.gov/pubmed/30429711
http://dx.doi.org/10.5114/ada.2018.77243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6232552/
https://www.ncbi.nlm.nih.gov/pubmed/30429711
http://dx.doi.org/10.5114/ada.2018.77243

Ejemplares similares